GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.

GSK announced that Health Canada has approved Ojjaara (momelotinib ... Results from the 24-week treatment period were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting ...

It’s possible to catch a cold or get the flu at any time of year. But the chances of becoming sick increase during cold and ...

With most myelofibrosis patients becoming anemic over time, Ojjaara's approval represents a significant milestone to improve the outcomes of these patients while also highlighting GSK's commitment ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

50 – 80 years of age Have a 20 pack-year history of smoking (1 pack a day for 20 years or 2 packs a day for 10 years) Are a current smoker or have quit within the last 15 years If you meet the ...

ASHG welcomed eight 2024–2026 Human Genetics Scholars who are recognized for their accomplishments and commitment to fostering DEI in human genetics and genomics.

With a rich background in brand positioning, Laura brings a wealth of strategic experience partnering with renowned organizations including Keurig Dr Pepper, Nestle, American Cancer Society, Merck, ...

GSK GSK-1.51%decrease; red down pointing triangle cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations in the third quarter due ...